Healthcare
Eupraxia Pharmaceuticals Inc.(EPRX)
Live Price
Offline$6.64
+2.47% today
1Y Change
+45.01%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $260.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -38.2%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Eupraxia Pharmaceuticals Inc. (EPRX) is a Healthcare stock with a market cap of $260.00M and listed on NASDAQ. The stock last traded around $6.64 and up 45.0% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -38.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -38.2%, free cash flow +1.6% with operating margin 0.0% and ROIC -51.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EPRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -38.2%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +8.6% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +4.3% | +4.7% | -12.9% |
2026 Mar 12, 2026 | -131.3% | -1.9% | +1.3% | -8.5% |
2025 Nov 4, 2025 | +17.4% | +4.0% | +19.8% | +9.3% |
Benchmark Edge
EPRX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EPRX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EPRX Max Drawdown
-34.73%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EPRX and SPY.
Company Overview
Eupraxia Pharmaceuticals Inc.
NASDAQ Global Market
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
- Leadership
- James A. Helliwell
- IPO Date
- Apr 5, 2024
- Employees
- 33
- Street Address
- 2067 Cadboro Bay Road
- Mailing
- Victoria, BC, V8R 5G4
- Region
- Victoria, BC, CA
- Reporting Currency
- USD
- Investor Line
- 250 590 3968
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 4.6
Growth
- Revenue
- 0.0%
- EPS
- -38.2%
- Free Cash Flow
- +1.6%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -63.8%
- ROIC
- -51.3%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 15.12
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.